赛升药业(300485.SZ)：子公司收到药品注册上市许可申请受理通知书

Core Viewpoint - The company, Sai Sheng Pharmaceutical, has received a notice from the National Medical Products Administration for the registration and marketing approval of Dapagliflozin Metformin Extended-Release Tablets, indicating a significant step in expanding its product portfolio in the diabetes treatment market [1] Group 1: Company Developments - Sai Sheng Pharmaceutical's subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application [1] - The combination drug Dapagliflozin and Metformin was developed by AstraZeneca and was approved by the FDA in 2014 [1] - The product was approved for marketing in China in June 2023, highlighting the company's progress in regulatory approvals [1] Group 2: Industry Insights - SGLT-2 inhibitors, like Dapagliflozin, work through a non-insulin-dependent mechanism, reducing glucose reabsorption in the kidneys and promoting glucose excretion through urine [1] - The combination of SGLT-2 inhibitors with Metformin has shown better glycemic control and lower side effects, indicating a potential competitive advantage in the diabetes treatment market [1]